Document is current
Any future updates will be listed below
-
Authors
Attiku, Yamini https://orcid.org/0000-0002-0229-8950
Nittala, Muneeswar Gupta https://orcid.org/0000-0002-3802-6594
Velaga, Swetha B. https://orcid.org/0000-0002-4637-6914
Ramachandra, Chaithanya
Bhat, Sandeep
Solanki, Kaushal
Jayadev, Chaitra https://orcid.org/0000-0001-8392-7159
Choudhry, Netan
Orr, Samantha Miyoko Ashlyn
Jiang, Shangjun
He, Ye
Sadda, SriniVas R.
- License Information
-
More Information
Article History
Received: 23 July 2022
Revised: 20 December 2022
Accepted: 7 February 2023
First Online: 10 May 2023
Competing interests
: YA, MGN, SBV (None), CR: Eyenuk, Inc. (E), SB: Eyenuk, Inc. (E), KS: Eyenuk, Inc. (E), CJ (None), NC: Abbvie (C,S) Apellis ©, Bayer (C,S,R), Novartis (C), Bausch & Lomb (C), Alcon (C), Optos PLC (S,C,R), Topcon (S,C,R), Hoffman La Roche (C), SriniVas R Sadda: Amgen (C), Allergan (C), Genentech/Roche (C), Iveric (C), Oxurion (C), Novartis (C), Regeneron (C), Bayer (C), 4DMT (C), Centervue (C,R), Heidelberg (C,R), Optos (C,R), Merck (C), Apellis (C), Astellas (C), Carl Zeiss Meditec (R), Nidek (R), Topcon (R). The authors declare no competing interests.
